Cerus Secures $10 Million Revolving Credit Facility

CONCORD, Calif.--(Business Wire)--
Cerus Corporation (NASDAQ:CERS) announced today that it has
obtained a $10 million senior revolving line of credit from Wells
Fargo Bank, N.A. Terms of the credit facility allow Cerus to draw down
funds as needed for working capital and general corporate purposes.
Interest is payable monthly at Cerus' option either at the bank's
prime rate or LIBOR plus 2.00% on any outstanding balance. Principal
is to be repaid by Cerus at the end of a one year term if the credit
facility is not extended. The revolving credit facility is secured by
the company's assets.

"We are pleased to have put in place a non-dilutive credit
facility on attractive terms with Wells Fargo Bank," said William J.
Dawson, vice president, finance and CFO of Cerus Corporation. "We
believe this credit facility will serve us well as our commercial
business expands and working capital needs grow."

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety.
The INTERCEPT Blood System is designed to inactivate blood-borne
pathogens in donated blood components intended for transfusion. Cerus
currently markets the INTERCEPT Blood System for both platelets and
plasma in Europe and the Middle East. The company is also pursuing
regulatory approvals in the United States and other countries. The
INTERCEPT red blood cell system is currently in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.

This press release contains forward-looking statements. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to the adequacy of
the credit facility to support expansion of the company's commercial
operations and growth of its working capital. Actual results could
differ materially from these forward-looking statements as a result of
certain factors, including, without limitation, risks associated with
the development, commercialization and market acceptance of the
INTERCEPT Blood System, as well as other risks detailed in the
company's filings with the Securities and Exchange Commission,
including the company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2007, and the quarterly report of Form 10-Q for the
quarter ended March 31, 2008. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. The company does not undertake any
obligation to update any forward-looking statements as a result of new
information, future events, changed assumptions or otherwise.

Cerus Corporation
William J. Dawson, Vice President, Finance & CFO
925-288-6053
or
Porter Novelli Life Sciences
Jason I. Spark, 619-849-6005

Copyright Business Wire 2008